Genetically encoding multiple functionalities into extracellular vesicles for the targeted delivery of biologics to T cells

Nat Biomed Eng. 2024 Apr;8(4):397-414. doi: 10.1038/s41551-023-01142-x. Epub 2023 Nov 27.

Abstract

The genetic modification of T cells has advanced cellular immunotherapies, yet the delivery of biologics specifically to T cells remains challenging. Here we report a suite of methods for the genetic engineering of cells to produce extracellular vesicles (EVs)-which naturally encapsulate and transfer proteins and nucleic acids between cells-for the targeted delivery of biologics to T cells without the need for chemical modifications. Specifically, the engineered cells secreted EVs that actively loaded protein cargo via a protein tag and that displayed high-affinity T-cell-targeting domains and fusogenic glycoproteins. We validated the methods by engineering EVs that delivered Cas9-single-guide-RNA complexes to ablate the gene encoding the C-X-C chemokine co-receptor type 4 in primary human CD4+ T cells. The strategy is amenable to the targeted delivery of biologics to other cell types.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products*
  • CD4-Positive T-Lymphocytes / metabolism
  • CRISPR-Cas Systems / genetics
  • Drug Delivery Systems / methods
  • Extracellular Vesicles* / metabolism
  • Genetic Engineering / methods
  • HEK293 Cells
  • Humans
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism

Substances

  • Biological Products